Baxalta
Takeda ordered to pay Bayer $155.19 million over patent infringement
February 6, 2019Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate
A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …
Shire shifts vaccine facility from Baxalta deal to MSD
August 8, 2017Manufacturing and Production Baxalta, MSD, Shire, biotech, drugs, pharma, pharmaceutical
As part of Shire’s mega-merger with Baxalta, it suddenly had a massive manufacturing network that spanned 17 sites across seven …
Shire Q2 results outpace forecasts with 56% revenue growth
August 2, 2016Research and Development, Sales and Marketing Baxalta, Shire, financial report
Shire has announced its fiscal results for Q2 2016, reporting a strong quarter with a 56% growth in total revenues …
Shire and BMS secure NICE recommendations for oncology drugs
July 27, 2016Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
Shire completes Baxalta takeover
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales
UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT). The …
Baxalta sues Chugai for haemophilia drug patent breach
May 11, 2016Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing
Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …
Baxter hikes 2016 earnings view driven by strong Q1 results
April 27, 2016Research and Development, Sales and Marketing Baxalta, FY, Q1, baxter, earnings, outlook, results, revenue
Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. The company now sees earnings …
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
April 7, 2016Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
Baxter to cut stake in Baxalta
March 17, 2016Business Services, Sales and Marketing Baxalta, Shares, Stake sale, baxter
Baxalta Inc (NYSE: BXLT) said former parent company Baxter International (NYSE: BAX) is set to cut its stake in the …
Onconova says Baxalta ends $565 million drug development deal for rigosertib
March 8, 2016Manufacturing and Production, Research and Development Baxalta, Onconova Therapeutics, drug development, rigosertib
Onconova Therapeutics says Baxalta has terminated its $565 million agreement to jointly develop the company’s lead drug candidate rigosertib. Baxalta …
Baxalta seeks European marketing rights for haemophilia drug
March 3, 2016Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta
Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …
Baxalta’s Enbrel biosimilar measures up in late-stage study
January 13, 2016Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis
Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …
Shire and Baxalta reach $32 billion merger agreement
January 11, 2016Manufacturing and Production, Sales and Marketing Baxalta, Shire, mergers, mergers and acquisitions
One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …
Bayer and Baxalta in separate €1 billion-plus deals
January 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ascensia diabetes care, Baxalta, Bayer, diabetes, panasonic, symphogen
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …
Reports: $32bn Shire takeover of Baxalta close to done deal
January 4, 2016Sales and Marketing Baxalta, Shire, acquisition, merger
The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to …
